Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"image","alt":"Kiniksa Pharmaceuticals International, Plc","displaySize":"","headline":null,"caption":"Kiniksa Pharmaceuticals International, Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":207,"url":"https://media.zenfs.com/en/globenewswire.com/84bc4259d2877b369755dfd109eaa0a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r5gTs1Se5SkGLArtdTldow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5MA--/https://media.zenfs.com/en/globenewswire.com/84bc4259d2877b369755dfd109eaa0a5","width":300,"height":207}},"lazy":false},{"type":"text","content":"LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.","length":305,"tagName":"p"},{"type":"text","content":"A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.","length":554,"tagName":"p"},{"type":"text","content":"About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.","length":478,"tagName":"p"},{"type":"text","content":"Every Second Counts! ®","length":22,"tagName":"p"},{"type":"text","content":"Kiniksa Investor & Media ContactJonathan Kirshenbaum(781) [email protected]","length":97,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]

More updates from Kiniksa Pharmaceuticals International, Plc